BeOne Medicines valuation
Secondary listing. The primary listing is BeOne Medicines · NASDAQ (USD)
¥264.41Change from previous close: +1.91%Absolute change: +¥4.95
Valuation
The P/E ratio is 91.8. The average price target of 8 analysts is ¥364.41.
Data as of October 4, 2026
Valuation multiples
- Market cap
- ¥388.84B
- Enterprise value
- ¥387.78B
- P/E (trailing 12 months)
- 91.8
- Forward P/E
- 48.4
- PEG
- 1.08
- Price/book
- 11.2
- Price/sales
- 63.4
- EV/EBITDA
- 361.9
- EV/revenue
- 63.3
Profitability and growth
- Gross margin
- 88.9%
- Operating margin
- 19.1%
- Net margin
- 10.7%
- ROE
- 14.7%
- ROA
- 7.5%
- Revenue growth (year over year)
- 29.6%
- Earnings growth (year over year)
- 166.7%
Financial health
- Total cash
- ¥5.1B
- Total debt
- ¥2.05B
- Debt/equity
- 0.40
- Current ratio
- 3.41
- Quick ratio
- 2.91
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- ¥364.41
- Median price target
- ¥357.05
- High price target
- ¥454.10
- Low price target
- ¥273.00
- Analysts with a price target
- 8
- Consensus
- Strong buy
- Forward EPS
- ¥5.46
- EPS estimate, current year
- ¥3.97
Shares and trading
- Beta
- 0.52
- Average volume
- 5.1M
- Shares outstanding
- 115.06M
- Float
- 1.05B
- Institutional ownership
- 29.5%
- Insider ownership
- 2.6%